Format

Send to

Choose Destination
Surg Clin North Am. 2015 Jun;95(3):653-67. doi: 10.1016/j.suc.2015.02.016.

Endoscopic treatment of gastroesophageal reflux disease.

Author information

1
Department of Surgery, University of South Alabama College of Medicine, Mastin Building, 2451 Fillingim Street, Mobile, AL 36617, USA.
2
Department of Surgery, University of South Alabama College of Medicine, Mastin Building, 2451 Fillingim Street, Mobile, AL 36617, USA. Electronic address: brichards@health.southalabama.edu.

Abstract

Multiple new endoluminal devices and therapies have been devised to create a more effective antireflux barrier in patients with gastroesophageal reflux disease (GERD). Most of these therapies have been abandoned, because they were ineffective and/or had significant adverse effects. However, there are currently two therapies (Stretta, EsophyX) that have US Food and Drug Administration approval and continue to be used in select patients with GERD. The clinical management of GERD, disease complications, endoluminal techniques, evidence for efficacy, and controversies concerning endoluminal therapy for GERD are reviewed and discussed.

KEYWORDS:

Endoluminal devices; EsophyX; Gastroesophageal reflux disease; Stretta

PMID:
25965137
DOI:
10.1016/j.suc.2015.02.016
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center